Refine
Has Fulltext
- yes (324)
Is part of the Bibliography
- yes (324) (remove)
Year of publication
Document Type
- Journal article (324) (remove)
Language
- English (324) (remove)
Keywords
- ischemic stroke (26)
- Parkinson’s disease (16)
- deep brain stimulation (15)
- multiple sclerosis (15)
- Fabry disease (14)
- Parkinson's disease (14)
- neuroinflammation (14)
- stroke (12)
- Medizin (11)
- inflammation (9)
- neuropathic pain (9)
- pain (8)
- neurology (7)
- subthalamic nucleus (7)
- B cells (6)
- acute ischemic stroke (6)
- biomarker (6)
- dopamine (6)
- dystonia (6)
- fibromyalgia syndrome (6)
- mouse model (6)
- MS (5)
- antibodies (5)
- blood-brain barrier (5)
- cytokines (5)
- depression (5)
- neurodegeneration (5)
- neuroprotection (5)
- traumatic brain injury (5)
- tremor (5)
- GFAP (4)
- MRI (4)
- blood–brain barrier (4)
- disease (4)
- factor XII (4)
- immunohistochemistry (4)
- macrophages (4)
- magnetic resonance imaging (4)
- mechanical thrombectomy (4)
- middle cerebral artery occlusion (4)
- movement disorders (4)
- mutation (4)
- neuropathy (4)
- platelets (4)
- small fiber neuropathy (4)
- thrombo-inflammation (4)
- walking (4)
- COVID-19 (3)
- EAE (3)
- Fabry-associated pain (3)
- Gehirn (3)
- HBMEC (3)
- Mice (3)
- Multiple sclerosis (3)
- Neurodegeneration (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- Pain (3)
- Parkinson disease (3)
- Ureaplasma parvum (3)
- animal models (3)
- autoantibodies (3)
- basal ganglia (3)
- biomarkers (3)
- brain (3)
- cerebellar tDCS (3)
- cerebral ischemia (3)
- cervical dystonia (3)
- children (3)
- closed head injury (3)
- criteria (3)
- enzyme replacement therapy (3)
- essential tremor (3)
- experimental autoimmune encephalomyelitis (3)
- experimental stroke (3)
- expression (3)
- gait initiation (3)
- gene expression (3)
- genetics (3)
- inflammasome (3)
- kinematics (3)
- length of stenosis (3)
- local field potentials (3)
- lymphocytes (3)
- macrophage (3)
- mesencephalic locomotor region (3)
- mice (3)
- myelin (3)
- neuroimmunology (3)
- neutrophils (3)
- photothrombotic stroke (3)
- quality of life (3)
- regulatory T cells (3)
- skin punch biopsy (3)
- tMCAO (3)
- therapy (3)
- tight junctions (3)
- transplantation (3)
- trial (3)
- Alzheimer’s disease (2)
- Autoantibodies (2)
- B7-H1 (2)
- Cerebrospinal fluid (2)
- Charcot-Marie-Tooth (2)
- DYT1 (2)
- Diagnosis (2)
- ELISPOT (2)
- Enzyme replacement therapy (2)
- Fabry genotype (2)
- Fabry phenotype (2)
- Fibromyalgia syndrome (2)
- Glatiramer acetate (2)
- Guillain-Barre-Syndrome (2)
- Inflammation (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- Maus (2)
- Mechanisms (2)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (2)
- NEUROWIND (2)
- NLRP3 (2)
- NOAC (2)
- Neuronal ceroid lipofuscinosis (2)
- Neuropathy (2)
- Outcome survey (2)
- PET (2)
- Schlaganfall (2)
- T cells (2)
- T lymphocytes (2)
- T-lymphocytes (2)
- Tourette syndrome (2)
- Treatment (2)
- Ureaplasma urealyticum (2)
- accuracy (2)
- adaptive immune system (2)
- amyotrophic-lateral-sclerosis (2)
- anxiety (2)
- atrial fibrillation (2)
- autoantibody (2)
- base of support (2)
- beta oscillations (2)
- binding (2)
- blood brain barrier (2)
- blood flow (2)
- blood pressure (2)
- c-Fos (2)
- carotid atherosclerosis (2)
- carotid stenosis (2)
- carotid ultrasound (2)
- central nervous system (2)
- cerebral autoregulation (2)
- cerebrovascular disorders (2)
- chronic cerebrovascular disease (2)
- chronic pain (2)
- cognitive impairment (2)
- colony-stimulating factor (2)
- contact-kinin system (2)
- degree of stenosis (2)
- dementia (2)
- diagnosis (2)
- diagnostic markers (2)
- differential diagnosis (2)
- dimethyl fumarate (2)
- disability (2)
- diseases of the nervous system (2)
- echocardiography (2)
- edema (2)
- electrophysiology (2)
- endoglin (2)
- endothelial cells (2)
- fibromyalgia (2)
- gait (2)
- gait analysis (2)
- gene (2)
- generalized cerebral edema (2)
- glial fate modulation (2)
- globotriaosylceramide (2)
- glycoprotein receptor Ib (2)
- guidelines (2)
- hearing loss (2)
- heart failure (2)
- hypoxia (2)
- immune cells (2)
- immunomodulation (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- ion channels (2)
- ischemic penumbra (2)
- lesions (2)
- leukocytes (2)
- locus coeruleus (2)
- machine learning (2)
- major depression (2)
- meningitis (2)
- microRNA (2)
- microglia (2)
- mitochondria (2)
- mortality (2)
- mouse models (2)
- multiple system atrophy (2)
- multiple-sclerosis (2)
- nerve fibers (2)
- neurofilament light chain (2)
- neurological disorders (2)
- neurons (2)
- opioids (2)
- outcomes (2)
- pathogenesis (2)
- photothrombosis (2)
- polyneuropathy (2)
- predictive value (2)
- protein (2)
- randomized controlled trial (2)
- rat (2)
- relapse (2)
- renal system (2)
- reversible posterior leukoencephalopathy syndrome (2)
- second hit (2)
- spinal cord (2)
- split-belt treadmill (2)
- synaptic vesicles (2)
- thrombosis (2)
- transient ischemic attack (2)
- transient middle cerebral artery occlusion (2)
- velocity (2)
- voluntary movement (2)
- von Willebrand factor (2)
- 2B (1)
- 3D fluoroscopy (1)
- 5IA-SPECT (1)
- 65-kda isoform (1)
- A-delta fibers (1)
- A53T (1)
- ADHD (1)
- ALS (1)
- ALS mimic (1)
- ALS treatment (1)
- ALSIN gene (1)
- APERIO (1)
- APERIO Hybrid (1)
- ASC (1)
- Adaptive cell transfer (1)
- Adult patients (1)
- Agalsidase beta (1)
- Agalsidase beta therapy (1)
- Alemtuzumab (1)
- Alpha galactosidase (1)
- Alzheimer disease (1)
- Alzheimer’s dementia (1)
- Amplitude (1)
- Amyotrophic Lateral Sclerosis (ALS) (1)
- Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5) (1)
- Anderson-Fabry Disease (1)
- Animal models (1)
- Antibody index (1)
- Antiparanodal Autoantibodies (1)
- Anxiety (1)
- Apoptosis (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Arterial Diameters (1)
- Arterial water (1)
- Ataxia (1)
- Atrial fibrillation (1)
- Axon degeneration (1)
- Axonal degeneration (1)
- Azathioprine (1)
- Aδ- and C-fibers (1)
- B-lymphocytes (1)
- BB/OKL rats (1)
- Barkhof criteria (1)
- Beta-glucocerebrosidase (1)
- Biomarker (1)
- Braak (1)
- Brain (1)
- Brain atrophy (1)
- Brain edema (1)
- Brain ischemia (1)
- Brainstem encephalitis (1)
- C.376A>G (p.S126G) (1)
- C1-inhibitor (1)
- C57BL/6 mice (1)
- CCI (1)
- CCS (1)
- CD105 (1)
- CD133 (1)
- CD52 (1)
- CIDP (1)
- CLN3 (1)
- CMV (1)
- CNS (1)
- CNS Myelination (1)
- CNS disease (1)
- CNS imaging (1)
- CNS integrity (1)
- COMPLEX 1 (1)
- COU254 (1)
- CRPS (1)
- CSF (1)
- CSVD (1)
- CXCL4 (1)
- CXCL5 (1)
- CXCL7 (1)
- CXCL8 (1)
- CXCR2 (1)
- Ca2+ homeostasis (1)
- Ca2+ ion analysis (1)
- Ca2+ leak (1)
- Ca2+ oscillation (1)
- Capsaicin receptor (1)
- Caspase (1)
- Cell Index (1)
- Cell therapy (1)
- Cell-based assays (1)
- Cerebellitis (1)
- Cerebral blood flow (1)
- Cerebral small vessel disease (1)
- Cerebral vasospasm (1)
- Cerebral-ischemia (1)
- Charcot-Marie-Tooth disease (1)
- Charcot–Marie–Tooth disease (1)
- Charcot–Marie–Tooth disease type 1A (1)
- CholinomiRs (1)
- Chronic heart failure (1)
- Chronic neuropathic pain (1)
- Cisterna magna (1)
- Clinical manifestations (1)
- Clinically silent stroke (1)
- Coefficient (1)
- Cognitive behavior (1)
- Cognitive decline (1)
- Cold (1)
- Computertomographie (1)
- Corneal confocal microscopy (1)
- Crespi effect (1)
- Cytokines (1)
- D313Y genotype (1)
- DARPA (1)
- DBS biomarkers (1)
- DBS programming (1)
- DOPA-responsive-dystonia (1)
- Deflazacort (1)
- Delphi procedure (1)
- Demyelinating peripheral neuropathy (1)
- Devic’s syndrome (1)
- Diabetes mellitus (1)
- Diabetic polyneuropathy (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Disease (1)
- Donor lymphocytes (1)
- Dose reduction (1)
- Double hemorrhage model (1)
- Duchenne dystrphy (1)
- Durchblutung (1)
- Dystonia (1)
- EEG data (1)
- ER Ca2+ imaging (1)
- ER Ca2+ store (1)
- ERK1/2 (1)
- Edema (1)
- El Escorial (1)
- Electrophysiology (1)
- English version (1)
- Epilepsy (1)
- EuroQol Five Dimension Five Level Scale (EQ-5D-5L) (1)
- Evoked potentials (1)
- Experimental stroke (1)
- Expression (1)
- F-18-FDG PET (1)
- FOSMN (1)
- FP-CIT SPECT (1)
- FTY720 (1)
- FTY720-P (1)
- FXII (1)
- FXIIa inhibitor rHA-Infestin (1)
- Fabry (1)
- Fabry cardiomyopathy (1)
- Fabry nephropathy (1)
- Facial nerve palsy (1)
- Factor messenger-RNA (1)
- Fc-receptor (1)
- Fibromyalgia (1)
- Fibromyalgie (1)
- Frabin/Fgd4 (1)
- GABAergic neurons (1)
- GCH1 (1)
- GFAP-astrocytopathies (1)
- GRAID (1)
- Gene-expression (1)
- Gland (1)
- Glial fibrillary acidic protein (1)
- Glioblastoma (1)
- Glioma stem cells (1)
- Glutamic-acid decarboxylase anxiety (1)
- Guillain-Barré syndrome (1)
- Guillain-Barré-Syndrom (1)
- HMGB1 (1)
- Head-injury (1)
- Hearing loss (1)
- Heat Hyperalgesia (1)
- Hemodynamic depression (1)
- Hyperalgesia (1)
- IBA-1 (1)
- IL-15 (1)
- IL-22 binding protein isoform (1)
- IL-4 (1)
- IL22RA2 (1)
- IPND criteria (1)
- IVIg (1)
- Identification (1)
- IgG (1)
- Immune system (1)
- Infections (1)
- Innervation (1)
- Insulin (1)
- IntelliCage (1)
- Interferon beta (1)
- Interleukin-18 (1)
- Interleukin-6 (1)
- Interleukin-6-Deficient mice (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Intravascular coagulation (1)
- Ischemia (1)
- Ischemic stroke (1)
- JCV (1)
- K+ channel (1)
- K2P channels (1)
- KCNK5 (1)
- K\(_{2P}\)5.1 (1)
- Kaliumkanal (1)
- L-DOPA (1)
- LI-rTMS (1)
- LIMP-2 (1)
- LSVT-big therapy (1)
- LTD (1)
- Langerhans cells (1)
- Leukemia Inhibitory Factor (1)
- Lewy-like pathology (1)
- Limb girdle muscular dystrophy (LGMD) (1)
- Longitudinally extensive transverse myelitis (1)
- Lysosomal storage disease (1)
- MCC950 (1)
- MDL-28170 (1)
- MIBG scintigraphy (1)
- MIC ligands (1)
- MMP9 (1)
- MOC fibers (1)
- MOG-IgG (1)
- MRI criteria (1)
- MSSS (1)
- Macrophage (1)
- Macrophages (1)
- Magnetic resonance imaging (1)
- Magnetic-resonance (1)
- McDonald criteria (1)
- Mediated Inflammatory Hyperalgesia (1)
- Memory dysfunction (1)
- Meningitis (1)
- Merkel cell density (1)
- Mesenchymal stem/stromal cells (1)
- Methotrexate (1)
- Microglia (1)
- Migräne (1)
- Miyoshi myopathy (1)
- Model (1)
- Molecular-weight heparin (1)
- Monopolar depression (1)
- Motor cortex (1)
- Motor nerve biopsy (1)
- Motor plasticity (1)
- Mucopolysaccharidosis IIIa (1)
- Multiple Sklerose (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelitis (1)
- Myeloma (1)
- NADPH oxidase inhibitors (1)
- NAP-2 (1)
- NETs (1)
- NF-\(\kappa\)B (1)
- NF-κB (1)
- NKG2D (1)
- NKG2D ligands (1)
- NMO-IGG (1)
- NMOSD (1)
- NMR-Tomographie (1)
- NPC1 gene (1)
- NPC2 gene (1)
- NPSI (1)
- Natalizumab (1)
- Necrosis-factor-Alpha (1)
- Nerve growth-factorcopy (1)
- Nestin (1)
- Neuralgie (1)
- Neurogenic inflammation (1)
- Neuroinflammation (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neurotrophic factors (1)
- Neutrophil (1)
- NfL (1)
- Niemann–Pick disease type C (1)
- Nodo-parandopathy (1)
- OCB (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Oncostatin-M-Receptor (1)
- Opioid receptor (1)
- Optical coherence tomography (1)
- Orai2 (1)
- Oral anticoagulation (1)
- Osteopontin (1)
- Outcome (1)
- PD-L1 (1)
- PF4 (1)
- PI3K isoforms (1)
- PML (1)
- PPAR-gamme (1)
- Pain questionnaire (1)
- Pain-related evoked potentials (1)
- Paradoxical heat sensation (1)
- Parkinson (1)
- Parkinsons disease (1)
- Parkionson's disease (1)
- Perfusion (1)
- Peripheral Inflammation (1)
- Peripheral nervous system (1)
- Pharmacological management (1)
- Plasma extravasation (1)
- Pleckstrin homology containing family member 5 (Plekhg5) (1)
- Pointing error (1)
- Pregnancy (1)
- Prodigy (1)
- Progressive supranuclear palsy (1)
- Proprioception (1)
- Quality of life (1)
- R-715 (1)
- RECK (1)
- RKIP (1)
- RNA extraction (1)
- Randomized controlled trial (1)
- Randomized controlled-trial (1)
- Rat (1)
- Rat Sensory Neurons (1)
- Rats (1)
- Receptors (1)
- Regenerative medicine (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Rheumatoid-Arthritis (1)
- Rho-GTPase Cdc42 (1)
- Rhombencephalitis (1)
- Richardson-Olszewski-Syndrome (1)
- Rituximab (1)
- Rochester diabetic neuropathy (1)
- SARS-CoV (1)
- SB332235 (1)
- SERCA (1)
- SHRSP (1)
- SNI (1)
- SOD1 mutations (1)
- SPG4 (1)
- SREBP (1)
- STAIR (1)
- STEMI (1)
- Schwann cell (1)
- Schwann cell dedifferentiation (1)
- Schwann cell differentiation (1)
- Schwann-cells (1)
- Screening questionnaire (1)
- Secondary stroke prevention (1)
- Sensitivity (1)
- Serotonin (1)
- Silver-syndrome (1)
- Sjorgens-syndrome (1)
- Skelettmuskel (1)
- Skin biopsy (1)
- Small fiber dysfunction (1)
- Small fiber neuropathy (1)
- Small-fiber neuropathy (1)
- Sonic hedgehog (1)
- Sphingosine 1-Phosphate (1)
- Stim (1)
- Stimuli (1)
- Stroke (1)
- Stroke unit (1)
- Subarachnoid (1)
- Subarachnoid hemorrhage (1)
- Survey (1)
- System involvement (1)
- T cell activation (1)
- T-PA (1)
- T-cells (1)
- TASK2 (1)
- TBI (1)
- TDMT (1)
- TIMP-1 (1)
- TIND (1)
- TLO (1)
- TMS (1)
- TNF-α (1)
- TNFα (1)
- TOR1A (1)
- TRP Channels (1)
- TSPO (1)
- Tdp-43 (1)
- Therapy (1)
- Thermal Hyperalgesia (1)
- Thrombus (1)
- Thrombus formation (1)
- Training (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Tryptophan hydroxylase-2 (Tph2) (1)
- Tuberkulose (1)
- Type 1 diabetes (1)
- Ureaplasma species (1)
- VCAM-1 (1)
- Vaccination (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Von-Willebrand-factor (1)
- Western blot (1)
- Wingerchuk criteria 2006 and 2015 (1)
- X-chromosomal inactivation (1)
- XAV-939 (1)
- Zonula Occludens-1 (1)
- [18F]FDG positron emission tomography (1)
- acid sphingomyelinase (1)
- activation (1)
- acute lymphoblastic leukaemia (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adhesion molecules (1)
- adrenal medulla (1)
- adult-onset (1)
- advanced therapy medicinal products (1)
- afferents (1)
- age (1)
- aggression (1)
- aging (1)
- albumin (1)
- algorithm (1)
- alias pilot trial (1)
- allodynia (1)
- alpha-7 nicotinic acetylcholine receptor (1)
- alpha-galactosidase A (1)
- alpha‐synuclein (1)
- alpha‐synuclein propagation (1)
- alpha‐synuclein seeding (1)
- amygdala (1)
- amyotrophic lateral sclerosis (1)
- analgesia (1)
- analgesic medication (1)
- aneurysm surgery (1)
- angiography (1)
- animal behavior (1)
- animal model (1)
- ankles (1)
- antagomir (1)
- anthropometric measurement (1)
- anthropometric measurements (1)
- anti-aquaporin-4 antibody (1)
- anti-contactin-1 (1)
- anticoagulants (1)
- anticoagulation (1)
- antidepressants (1)
- antigen-presenting cells (1)
- apoE (1)
- apoe (1)
- apomorphine (1)
- aquaporin 4 (1)
- aquaporin-4 autoantibodies (1)
- areas (1)
- arm (1)
- artery occlusion (1)
- assistive devices (1)
- association (1)
- association studies in genetics (1)
- astrocyte (1)
- astrocytes (1)
- astrogliosis (1)
- atherosclerosis (1)
- atrophy Kennedys-disease (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attenuation of disease (1)
- atypical chemokine receptor 3 (1)
- autoantibody (aAb) (1)
- autoimmune (1)
- autoimmune neuroinflammation (1)
- autophagy (1)
- autoradiography (1)
- axonal degeneration (1)
- axonal integrity (1)
- axonal transcriptome (1)
- axonal transport (1)
- axonopathic changes (1)
- back pain (1)
- balance (1)
- barrier (1)
- barrier integrity (1)
- basal forebrain cholinergic neurons (1)
- behavioral disorders (1)
- beta oscillation (1)
- beta power (1)
- bilateral internal carotid artery stenosis (1)
- bilateral motor network (1)
- binding analysis (1)
- biological locomotion (1)
- biopsies (1)
- biopsy (1)
- blood (1)
- blood coagulability (1)
- blood coagulation (1)
- blood nerve barrier (1)
- bone-marrow (1)
- botulinum toxin (1)
- bradykinesia (1)
- bradykinin (1)
- brain dynamics (1)
- brain edema (1)
- brain endothelium (1)
- brain metabolic alterations (1)
- brain networks (1)
- brain state (1)
- brain stem (1)
- burning pain (1)
- calpain (1)
- capsaicin (1)
- cardiac imaging (1)
- cardiac magnetic resonance imaging (1)
- cardiovascular disease (1)
- care (1)
- care tempis (1)
- caregiver (1)
- caregiver burden (1)
- case report (1)
- caudate nucleus (1)
- celiac disease (1)
- cell adhesion (1)
- cell binding assay (1)
- cellular therapy (1)
- cerebellar vermis hypoplasia (1)
- cerebellum (1)
- cerebral arteries (1)
- cerebral blood flow (1)
- cerebral inflammation (1)
- cerebral microbleeds (1)
- cerebral small vessel disease (1)
- cerebrospinal fluid (1)
- cerebrospinal fluid culture (1)
- cerebrospinal-fluid (1)
- cerebrovascular diseases (1)
- chemokines (1)
- chitinase-3-like protein 1 (1)
- choline acetyltransferase (1)
- cholinergic activity (1)
- cholinergic system (1)
- chronic constriction nerve injury (CCI) (1)
- chronic kidney disease (1)
- chronic stimulation (1)
- chronic stress (1)
- classification (1)
- claudin-1 (1)
- clinical approach (1)
- clinical diagnosis (1)
- clinical neurology (1)
- clinical outcome (1)
- clinical phenotype (1)
- clip control (1)
- closed-loop (1)
- coagulation (1)
- coagulation factor XIIa (1)
- cochlea (1)
- cognitive (1)
- cognitive decline (1)
- cognitive function (1)
- coherence (1)
- coherence analysis (1)
- collagens (1)
- collateral circulation (1)
- colony stimulating factor 1 (1)
- compensatory strategies (1)
- complement (1)
- complement deposition (1)
- comprehension (1)
- computed tomography (1)
- computer vision (1)
- consolidation (1)
- contact activation system (1)
- continuous theta burst stimulation (cTBS) (1)
- contrast (1)
- contrast-enhanced MRI (1)
- conversion (1)
- coordination (1)
- coping (1)
- corneal confocal microscopy (1)
- cortical activation (1)
- cortical excitability (1)
- cortical oscillatory activity (1)
- cortical pathology (1)
- cortical silent period (1)
- crossover trial (1)
- cue (1)
- cutaneous innervation (1)
- cutaneous patch (1)
- cutting edge (1)
- damage cool aid (1)
- darbepoetin alpha (1)
- data filtering (1)
- deep brain stimulation (DBS) (1)
- deep brain-stimulation (1)
- degeneration (1)
- delayed cerebral infarction (1)
- delays progression (1)
- demography (1)
- demyelinating disease (1)
- demyelinating polyradiculoneuropathy (1)
- demyelination (1)
- dendric cells (1)
- design (1)
- developmental signaling (1)
- diabetes mellitus (1)
- diabetic neuropathy (1)
- diagnosis in Fabry disease (1)
- diagnostic delay (1)
- diagnostic medicine (1)
- diagnostics (1)
- diffuse (1)
- digital medicine (1)
- directional deep brain stimulation (1)
- disease model (1)
- disease progression (1)
- disease severity (1)
- disease-modifying therapy (1)
- disorder (1)
- domain potassium channels (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- drug (1)
- duodenal levodopa infusion (1)
- dysferlinopathy (1)
- edoxaban (1)
- effects (1)
- efficacy (1)
- ejection fraction (1)
- electromyography (1)
- element (1)
- embolic stroke (1)
- emulsions (1)
- encephalitis (1)
- endothelin-1 (1)
- endotheliopathy (1)
- enteropathy (1)
- enzyme assays (1)
- enzyme-linked immunoassays (1)
- epidermis (1)
- event-related desynchronization (1)
- exercise (1)
- exome sequencing (1)
- experimental (1)
- experimental autoimmune neuritis (1)
- experimental design (1)
- expert opinion (1)
- extensiv transverse myelitis (1)
- eye movement disorders (1)
- facial pain (1)
- factor XI (1)
- familial amyloidotic polyneuropathy (1)
- family caregiver (1)
- fatigue (1)
- fear (1)
- fear memory (1)
- feasibility (1)
- female Fabry patients (1)
- females (1)
- fibers (1)
- fibroblast (1)
- finger-tapping task (1)
- fingolimod (1)
- flotillin-1 lipid rafts (1)
- fluorine (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral ischemia (1)
- focal cerebral-ischemia (1)
- fosfomycin (1)
- free radical scavenger (1)
- freezing of gait (1)
- freezing of gait (FOG) (1)
- fullerenes (1)
- functional MRI (1)
- functional neuroanatomy (1)
- fungal infection (1)
- future directions (1)
- gadofluorine (1)
- gadolinium-DTPA (1)
- gait modulation (1)
- gait-phase prediction (1)
- galactomannan (1)
- gender (1)
- gene mutations (1)
- gene variant (1)
- gene-by-environment interaction (1)
- gene-environment interaction (1)
- generalized cerebellar atrophy (1)
- genome-wide association study (1)
- genotype-phenotype correlation (1)
- genotype/phenotype correlation (1)
- gephyrin (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- glioblastoma multiforme (1)
- globus pallidus (1)
- globus pallidus pars interna (GPi) (1)
- glycation end products (1)
- glycine receptor (1)
- glycine receptor (GlyR) (1)
- glycine receptor autoantibodies (1)
- glycoprotein Ib (1)
- glycoprotein VI (1)
- glycoprotein receptor Ibα (1)
- granzyme B (1)
- gridle muscular-dystrophy (1)
- growth (1)
- growth pattern (1)
- health behavior (1)
- health-related quality of life (HRQoL) (1)
- hemicraniectomy (1)
- hemorrhagic transformation (1)
- hereditary motor and sensory neuropathy (1)
- hereditary spastic paraplegia (HSP) (1)
- hernia repair (1)
- hexanucleotide repeat (1)
- high contrast (1)
- hip (1)
- hippocampus (1)
- histology (1)
- homotypic fusion and protein sorting (1)
- hospitals (1)
- human brain endothelium (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- human muscle-cells (1)
- human neurons (1)
- humans (1)
- hyperalgesia (1)
- hypercholesterolemia (1)
- hyperekplexia (1)
- hypothermia (1)
- i.v. thrombolysis (1)
- idiopathic inflammatory myopathies (1)
- image quality (1)
- image-guided programming (1)
- imaging (1)
- immaturity (1)
- immune (1)
- immune system (1)
- immune-response (1)
- immunofluorescence (1)
- immunoglobulin-G (1)
- in-vivo (1)
- incidence (1)
- increased risk (1)
- induced neural stem cells (1)
- inducible expression (1)
- inertial measurement units (1)
- infantile neuronal ceroid lipofuscinosis (1)
- infarction (1)
- infarction size (1)
- infarction volume (1)
- inflammatory cascades (1)
- inflammatory demyelinating polyradiculoneuropathy (1)
- inflammatory neuropathy (1)
- informal care (1)
- informed consent (1)
- inherited metabolic disorders (1)
- inherited peripheral neuropathy (1)
- injection site reactions; (1)
- innate immune system (1)
- innervation (1)
- integrin α2 (1)
- integrins (1)
- interference (1)
- interleukin-1 receptor antagonist (1)
- interleukin-8 (1)
- internal carotid artery stenosis (1)
- internet-based intervention (1)
- interval timing (1)
- interview (1)
- intracranial bleeding (1)
- intracranial hemorrhage (1)
- intractable hiccup (1)
- intraepidermal nerve fiber density (1)
- intraepidermal nerve fibre density (1)
- intraoperative (1)
- intrathecal application (1)
- intravenous immunoglobulin (1)
- intravenous thrombolysis (1)
- invasive electric stimulation (1)
- ipsilateral motor evoked potential (1)
- ipsilateral motor network (1)
- iron (1)
- iron dyshomeostasis (1)
- iron oxide nanoparticles (1)
- ischemia (1)
- ischemia/reperfusion injury (1)
- ischemic cascade (1)
- just noticeable difference (JND) (1)
- kallikrein-kinin system (1)
- kallikrein–kinin system (1)
- kinesthesia (1)
- kinin receptor (1)
- kinin receptors (1)
- knees (1)
- large vessel occlusion (1)
- learning (1)
- levodopa-induced dyskinesia (1)
- linkage (1)
- liponeurocytoma (1)
- locomotion (1)
- locomotor adaptation (1)
- long-term pain (1)
- lymphokine-activated killer (1)
- lyso-Gb3 (1)
- lysosomal dysfunction (1)
- lysosomal enzyme (1)
- lysosomal storage disease (1)
- lyso‐Gb3 (1)
- magnesium (1)
- management (1)
- matrix metalloproteinases (1)
- mechanical energy (1)
- mechanisms (1)
- medial ganglionic eminence (1)
- medulloblastoma (1)
- mental health (1)
- mesenchymal stem and stromal cells (1)
- mesenchymal stem cells (1)
- metaanalysis (1)
- methylphenidate (1)
- miR-182-5p (1)
- miR-21 (1)
- miRNA (1)
- miRNA expression patterns (1)
- miRNA polymorphisms (1)
- miRNA-based analgesic (1)
- miRNA-based diagnostics (1)
- mice impact (1)
- microangiopathy (1)
- microscopy (1)
- microsphere/macrosphere (1)
- microtubules (1)
- midbrain (1)
- migraine (1)
- migraineur (1)
- mixed fiber neuropathy (1)
- mixed methods (1)
- molecular signature (1)
- monocycline (1)
- monocytes (1)
- monomethyl fumarate (1)
- motoneuron disease (1)
- motor (1)
- motor axonal neuropathy (1)
- motor control (1)
- motor cortex (1)
- motor evoked potential (MEP) (1)
- motor function (1)
- motor learning (1)
- motor neuron disease (1)
- motor neuropathy (1)
- motor proteins (1)
- motor-evoked potentials (MEP) (1)
- mouse (1)
- mouse brain microvascular endothelial cell cultur (1)
- movement (1)
- movements (1)
- multiple sklerosis (1)
- muscle atrophy (1)
- muscle strength (1)
- musical syntax (1)
- musk myasthenia gravis (1)
- myasthenia gravis (1)
- myelin biology and repair (1)
- myelination (1)
- myocardial infarction (1)
- natural history (1)
- near-infrared spectroscopy (1)
- neonatal meningitis (1)
- nerve biopsy (1)
- nerve fibres (1)
- nerve tumor (1)
- nerve-fibers (1)
- nervous system (1)
- nervous-system (1)
- neural apoptosis (1)
- neural stem cell (1)
- neural stem cells (1)
- neuralgia (1)
- neurobehavioural deficits (1)
- neuroborreliosis (1)
- neurocritical care (1)
- neurocytoma (1)
- neurofascin (1)
- neurofilaments (1)
- neuroleukemiosis (1)
- neurological complications (1)
- neurological examination (1)
- neuromelanin (1)
- neuronal apoptosis (1)
- neuronal differentiation (1)
- neuronal network (1)
- neuronal stem cells (1)
- neuronopathy (1)
- neurophysiology (1)
- neuroplasticity (1)
- neurorepair (1)
- neuroscience (1)
- neutrophil (1)
- nicotinamide (1)
- nicotinic receptors (1)
- nociceptor sensitization (1)
- nodes of Ranvier (1)
- non-motor features (1)
- nonalcoholic steatohepatitis (1)
- noradrenalin (1)
- noradrenaline (1)
- norepinephrine (1)
- novo renal transplantation (1)
- nucleus ventralis intermedius (1)
- nystagmus (1)
- object recognition memory (1)
- obstacle avoidance (1)
- occlusion (1)
- oligodendroglia (1)
- online systems (1)
- ontactin 1 (1)
- opioid (1)
- optical coherence tomography (1)
- outcome (1)
- outer hair cell (OHC) (1)
- oxidative stress (1)
- p.R245H (1)
- p.S298P (1)
- p38 mitogen-activated protein kinase (1)
- p57kip2 (1)
- pain pattern (1)
- pain questionnaire (1)
- pain sensation (1)
- pain-associated behavior (1)
- pain-related evoked potentials (1)
- pallidal stimulation (1)
- pandemic (1)
- paranodopathy (1)
- paraparesis (1)
- parkinson disease (1)
- parkinsons disease (1)
- passive transfer (1)
- pathology section (1)
- pathophysiology (1)
- pathway analysis (1)
- pathways (1)
- patient reported outcome measures (1)
- patient triage (1)
- pedunculopontine nucleus (PPN) (1)
- pegylated insulin-like growth factor 1 (1)
- peptide (1)
- periperal nerve (1)
- peripheral injury (1)
- peripheral nerve involvement (1)
- peripheral nervous system (1)
- peripheral nervous-system (1)
- peripheral neuropathy (1)
- permanent and transient middle cerebral artery occlusion (1)
- pet (1)
- ph (1)
- phosphorylated tau protein (1)
- physical activity (1)
- physical therapy modalities (1)
- pilot project (1)
- placebo-controlled (1)
- plaque cross-sectional area (1)
- plasma extravasation (1)
- plasma oxysterols (1)
- plasminogen (1)
- platelet activation (1)
- platelet aggregation (1)
- point-of-care echocardiography (1)
- pointing task (1)
- polymorphism (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- position estimation (1)
- post-processing (1)
- post-traumatic stress disorder (1)
- postherpetic neuralgia (1)
- postural control (1)
- posture (1)
- potassium channels (1)
- potent inducer (1)
- precision medicine (1)
- preclinical research (1)
- prednisone (1)
- prefrontal cortex (1)
- presynaptic inhibition (1)
- preterm birth (1)
- preventive treatment (1)
- prognosis (1)
- progression (1)
- progressive ataxia (1)
- progressive encephalitis with rigidity and myoclonus (PERM) (1)
- progressive supranuclear palsy (1)
- proinflammatory cytokine (1)
- protein and mRNA expression (1)
- proteins (1)
- proteolipid protein (1)
- proteolipid protein gene (1)
- proteomics (1)
- psychophysics (1)
- purmorphamine (1)
- quality (1)
- quality control (1)
- quality of life (QoL) (1)
- quality-control (1)
- quantitative sensory testing (1)
- qutenza (1)
- randomized controlled double-blind study (1)
- rat brain microvascular endothelial cell culture (1)
- rat hepatocytes (1)
- rats (1)
- reach-to-grasp movement (1)
- reaction-time tasks (1)
- receptor (1)
- receptor tyrosine kinase (1)
- recombinant tissue-type plasminogen activator (1)
- recommendations (1)
- recurrence (1)
- reflex (1)
- regional heterogeneity (1)
- regulation (1)
- regulatory cells (1)
- rehabilitation (1)
- reinnervation (1)
- relapsing multiple sclerosis (1)
- relapsing-remitting multiple sclerosis (1)
- religiosity (1)
- renal function (1)
- reoxygenation (1)
- reperfusion (1)
- reperfusion injury (1)
- reproducible outcome measure (1)
- reserpinized rat model (1)
- responsivity (1)
- resting tremor (1)
- retinal ganglion cells (1)
- retinocochleocerebral (1)
- rett (1)
- rhythm perception (1)
- risk (1)
- risk factors (1)
- risk of fall (1)
- rt-PA (1)
- scale (1)
- sciatic nerve (1)
- sciatic nerves (1)
- search filter (1)
- secondary infarct growth (1)
- secretome (1)
- segmental centers of mass (1)
- sensory neurons (1)
- serotonin (1)
- serum (1)
- sex addiction (1)
- shedding (1)
- shingles (1)
- signal peptide (1)
- single photon emission computed tomography (SPECT) (1)
- skilled forelimb movements (1)
- skin biopsy (1)
- skin diseases (1)
- skin tumors (1)
- small vessel disease (1)
- small-fiber neuropathy (1)
- software (1)
- soleus muscles (1)
- soluble endoglin (1)
- somatosensory temporal discrimination (1)
- somatosensory-evoked-potentials (1)
- sphingolipids (1)
- spinal cord injury (1)
- spinal muscular atrophy (1)
- spinal-cord (1)
- spinal-cord-injury (1)
- startle disease (1)
- stent-retriever device (1)
- steroids (1)
- stiff-person syndrome (SPS) (1)
- stimulation (1)
- store-operated Ca2+ entry (1)
- stress (1)
- striatum (1)
- stroke care (1)
- stroke unit (1)
- stromal cells (1)
- study (1)
- subarachnoid hemorrhage (1)
- subcutaneous injection (1)
- substance-P (1)
- subthalamic nucleus (STN) (1)
- swimming (1)
- switch (1)
- symptom-specific treatment (1)
- synapse (1)
- synaptic transmission (1)
- syndrome (1)
- system (1)
- systematic review (1)
- systems biology (1)
- systolic dysfunction (1)
- target considerations (1)
- task retention (1)
- telemedicine (1)
- telemedicine network (1)
- temporal discrimination threshold (1)
- teriflunomide (1)
- term follow-up (1)
- tetrahydroisoquinoline derivates (1)
- tetraparesis (1)
- thrombemboli (1)
- thromboemboli (1)
- thromboembolic clot model (1)
- thromboembolic stroke (1)
- thromboinflammation (1)
- thrombolysis (1)
- thrombus formation (1)
- tics (1)
- time (1)
- time perception (1)
- timing (1)
- tissue-plasminogen activator (1)
- tool (1)
- topography (1)
- torsinA (1)
- transcranial direct current stimulation (1)
- transcranial magnetic simulation (TMS) (1)
- transgenic mouse model (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion model (1)
- transient receptor potential vanilloid 1 (TRPV1) (1)
- translation (1)
- translational research (1)
- translational stroke research (1)
- transmission electron microscopy (1)
- treatment options (1)
- treatment-induced neuropathy in diabetes (TIND) (1)
- treatment-resistant depression (1)
- trigeminal nerve (1)
- trigeminal neuropathy (1)
- troponin (1)
- tuberculous meningitis (1)
- tumor immunity (1)
- ultrasound imaging (1)
- under-dosing (1)
- up-regulation (1)
- upper limb (1)
- validation (1)
- variants of unknown significance (1)
- vascular dementia (1)
- vascular homeostasis (1)
- vascular permeability (1)
- vasculopathy (1)
- vertebrobasilar insufficiency (1)
- vertigo (1)
- vessel patency (1)
- vestibular (1)
- videooculography (1)
- virtual reality (1)
- visual activity (1)
- visual pathways (1)
- volume regulation (1)
- weight drop (1)
- white blood cells (1)
- white matter disease (1)
- white matter hyperintensities (1)
- white matter lesions (1)
- α-Galactosidase A (1)
- α-synuclein (1)
- α-synuclein-specific T cells (1)
- α‐GalA 3D‐structure (1)
- β-APP (1)
- “bulbar-onset” ALS (bALS) (1)
- “limb-onset” ALS (lALS) (1)
Institute
- Neurologische Klinik und Poliklinik (324) (remove)
Sonstige beteiligte Institutionen
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Wurzburg Fabry Center for Interdisciplinary Therapy (FAZIT), Wurzburg, Germany (1)
- Würzburg Fabry Center for Interdisciplinary Therapy (FAZIT), University of Würzburg, Würzburg, Germany (1)
Background
Postherpetic neuralgia (PHN) is the painful complication of a varicella zoster virus reactivation. We investigated the systemic and local gene expression of pro- and anti-inflammatory cytokine expression in patients with PHN.
Methods
Thirteen patients with PHN at the torso (Th4-S1) were recruited. Skin punch biopsies were obtained from the painful and the contralateral painless body area for intraepidermal nerve fiber density (IENFD) and cytokine profiling. Additionally, blood was withdrawn for systemic cytokine expression and compared to blood values of healthy controls. We analyzed the gene expression of selected pro- and anti-inflammatory cytokines (tumor necrosis factor-alpha [TNF] and interleukins [IL]-1β, IL-2, and IL-8).
Results
IENFD was lower in affected skin compared to unaffected skin (p<0.05), while local gene expression of pro- and anti-inflammatory cytokines did not differ except for two patients who had 7fold higher IL-6 and 10fold higher IL-10 gene expression in the affected skin compared to the contralateral unaffected skin sample. Also, the systemic expression of cytokines in patients with PHN and in healthy controls was similar.
Conclusion
While the systemic and local expression of the investigated pro- and anti-inflammatory cytokines was not different from controls, this may have been influenced by study limitations like the low number of patients and different disease durations. Furthermore, other cytokines or pain mediators need to be considered.
Interleukin-4 (IL-4) is an anti-inflammatory and analgesic cytokine that induces opioid receptor transcription. We investigated IL-4 knockout (ko) mice to characterize their pain behavior before and after chronic constriction injury (CCI) of the sciatic nerve as a model for neuropathic pain. We investigated opioid responsivity and measured cytokine and opioid receptor gene expression in the peripheral and central nervous system (PNS, CNS) of IL-4 ko mice in comparison with wildtype (wt) mice. Naïve IL-4 ko mice displayed tactile allodynia (wt: 0.45 g; ko: 0.18 g; p<0.001), while responses to heat and cold stimuli and to muscle pressure were not different. No compensatory changes in the gene expression of tumor necrosis factor-alpha (TNF), IL-1β, IL-10, and IL-13 were found in the PNS and CNS of naïve IL-4 ko mice. However, IL-1β gene expression was stronger in the sciatic nerve of IL-4 ko mice (p<0.001) 28 days after CCI and only IL-4 ko mice had elevated IL-10 gene expression (p = 0.014). Remarkably, CCI induced TNF (p<0.01), IL-1β (p<0.05), IL-10 (p<0.05), and IL-13 (p<0.001) gene expression exclusively in the ipsilateral spinal cord of IL-4 ko mice. The compensatory overexpression of the anti-inflammatory and analgesic cytokines IL-10 and IL-13 in the spinal cord of IL-4 ko mice may explain the lack of genotype differences for pain behavior after CCI. Additionally, CCI induced gene expression of μ, κ, and δ opioid receptors in the contralateral cortex and thalamus of IL-4 ko mice, paralleled by fast onset of morphine analgesia, but not in wt mice. We conclude that a lack of IL-4 leads to mechanical sensitivity; the compensatory hyperexpression of analgesic cytokines and opioid receptors after CCI, in turn, protects IL-4 ko mice from enhanced pain behavior after nerve lesion.
High-Dose Capsaicin for the Treatment of Neuropathic Pain: What We Know and What We Need to Know
(2014)
Neuropathic pain is a frequent and disabling condition with diverse underlying etiologies and is often difficult to treat. Systemic drug treatment is often limited in efficacy. Furthermore, adverse effects may be a limiting factor when trying to reach the necessary dose. Analgesics that can be applied topically have the potential to largely overcome this problem. They may be of particular advantage in localized neuropathic pain syndromes such as postherpetic neuralgia or small fiber neuropathy. Capsaicin, the pungent component of chili peppers, is a natural ligand of the transient receptor potential vanilloid 1 channel and has long been used as topically applicable cream with concentrations of 0.025 to 0.075%. In 2009, a high-concentration transdermal capsaicin 8% patch (Qutenza ; Acorda Therapeutics, Inc., Ardsley, NY, USA; Astellas Pharma Europe Ltd., Chertsey, Surrey, UK) was introduced for the treatment of peripheral neuropathic pain syndromes other than of diabetic origin in adults. It has since been widely used in diverse neuropathic pain disorders. In this review article, we summarize current knowledge on Qutenza, its advantages and problems, and expose unmet needs.
Background
The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity.
Methods
At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data.
Results
We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy.
Conclusions
Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.
Objectives
The pathogenesis of fibromyalgia syndrome (FMS) is unclear. Transcranial ultrasonography revealed anechoic alteration of midbrain raphe in depression and anxiety disorders, suggesting affection of the central serotonergic system. Here, we assessed midbrain raphe echogenicity in FMS.
Methods
Sixty-six patients underwent transcranial sonography, of whom 53 were patients with FMS (27 women, 26 men), 13 patients with major depression and physical pain (all women), and 14 healthy controls (11 women, 3 men). Raphe echogenicity was graded visually as normal or hypoechogenic, and quantified by digitized image analysis, each by investigators blinded to the clinical diagnosis.
Results
Quantitative midbrain raphe echogenicity was lower in patients with FMS compared to healthy controls (p<0.05), but not different from that of patients with depression and accompanying physical pain. Pain and FMS symptom burden did not correlate with midbrain raphe echogenicity as well as the presence and severity of depressive symptoms.
Conclusion
We found reduced echogenicity of the midbrain raphe area in patients with FMS and in patients with depression and physical pain, independent of the presence or severity of pain, FMS, and depressive symptoms. Further exploration of this sonographic finding is necessary before this objective technique may enter diagnostic algorithms in FMS and depression.
Background
Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain and associated symptoms. We investigated cerebral activation in FMS patients by functional near-infrared spectroscopy (fNIRS).
Methods
Two stimulation paradigms were applied: a) painful pressure stimulation at the dorsal forearm; b) verbal fluency test (VFT). We prospectively recruited 25 FMS patients, ten patients with unipolar major depression (MD) without pain, and 35 healthy controls. All patients underwent neurological examination and all subjects were investigated with questionnaires (pain, depression, FMS, empathy).
Results
FMS patients had lower pressure pain thresholds than patients with MD and controls (p < 0.001) and reported higher pain intensity (p < 0.001). Upon unilateral pressure pain stimulation fNIRS recordings revealed increased bilateral cortical activation in FMS patients compared to controls (p < 0.05). FMS patients also displayed a stronger contralateral activity over the dorsolateral prefrontal cortex in direct comparison to patients with MD (p < 0.05). While all three groups performed equally well in the VFT, a frontal deficit in cortical activation was only found in patients with depression (p < 0.05). Performance and cortical activation correlated negatively in FMS patients (p < 0.05) and positively in patients with MD (p < 0.05).
Conclusion
Our data give further evidence for altered central nervous processing in patients with FMS and the distinction between FMS and MD.
Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls
(2014)
Background
Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization.
Methods
We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression.
Results
All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups.
Conclusions
Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS.
Background
Fabry disease is an inborn lysosomal storage disorder which is associated with small fiber neuropathy. We set out to investigate small fiber conduction in Fabry patients using pain-related evoked potentials (PREP).
Methods
In this case–control study we prospectively studied 76 consecutive Fabry patients for electrical small fiber conduction in correlation with small fiber function and morphology. Data were compared with healthy controls using non-parametric statistical tests. All patients underwent neurological examination and were investigated with pain and depression questionnaires. Small fiber function (quantitative sensory testing, QST), morphology (skin punch biopsy), and electrical conduction (PREP) were assessed and correlated. Patients were stratified for gender and disease severity as reflected by renal function.
Results
All Fabry patients (31 men, 45 women) had small fiber neuropathy. Men with Fabry disease showed impaired cold (p < 0.01) and warm perception (p < 0.05), while women did not differ from controls. Intraepidermal nerve fiber density (IENFD) was reduced at the lower leg (p < 0.001) and the back (p < 0.05) mainly of men with impaired renal function. When investigating A-delta fiber conduction with PREP, men but not women with Fabry disease had lower amplitudes upon stimulation at face (p < 0.01), hands (p < 0.05), and feet (p < 0.01) compared to controls. PREP amplitudes further decreased with advance in disease severity. PREP amplitudes and warm (p < 0.05) and cold detection thresholds (p < 0.01) at the feet correlated positively in male patients.
Conclusion
Small fiber conduction is impaired in men with Fabry disease and worsens with advanced disease severity. PREP are well-suited to measure A-delta fiber conduction.
A high load of white matter lesions and enlarged basilar arteries have been shown in selected patients with Fabry disease, a disorder associated with an increased stroke risk. We studied a large cohort of patients with Fabry disease to differentially investigate white matter lesion load and cerebral artery diameters. We retrospectively analyzed cranial magnetic resonance imaging scans of 87 consecutive Fabry patients, 20 patients with ischemic stroke, and 36 controls. We determined the white matter lesion load applying the Fazekas score on fluid-attenuated inversion recovery sequences and measured the diameters of cerebral arteries on 3D-reconstructions of the time-of-flight-MR-angiography scans. Data of different Fabry patient subgroups (males – females; normal – impaired renal function) were compared with data of patients with stroke and controls. A history of stroke or transient ischemic attacks was present in 4/30 males (13%) and 5/57 (9%) females with Fabry disease, all in the anterior circulation. Only one man with Fabry disease showed confluent cerebral white matter lesions in the Fazekas score assessment (1%). Male Fabry patients had a larger basilar artery (p<0.01) and posterior cerebral artery diameter (p<0.05) compared to male controls. This was independent of disease severity as measured by renal function and did not lead to changes in arterial blood flow properties. A basilar artery diameter of >3.2 mm distinguished between men with Fabry disease and controls (sensitivity: 87%, specificity: 86%, p<0.001), but not from stroke patients. Enlarged arterial diameters of the posterior circulation are present only in men with Fabry disease independent of disease severity.
Objective: We investigated cerebral opioid receptor binding potential in patients with fibromyalgia syndrome (FMS) using positron-emission-tomography (PET) and correlated our results with patients’ systemic interleukin-4 (IL-4) gene expression.
Methods: In this pilot study, seven FMS patients (1 man, 6 women) agreed to participate in experimental PET scans. All patients underwent neurological examination, were investigated with questionnaires for pain, depression, and FMS symptoms. Additionally, blood for IL-4 gene expression analysis was withdrawn at two time points with a median latency of 1.3 years. Patients were investigated in a PET scanner using the opioid receptor ligand F-18-fluoro-ethyl-diprenorphine ([18F]FEDPN) and results were compared with laboratory normative values.
Results: Neurological examination was normal in all FMS patients. Reduced opioid receptor binding was found in mid cingulate cortex compared to healthy controls (p < 0.005). Interestingly, three patients with high systemic IL-4 gene expression had increased opioid receptor binding in the fronto-basal cortex compared to those with low IL-4 gene expression (p < 0.005).
Conclusion: Our data give further evidence for a reduction in cortical opioid receptor availability in FMS patients as another potential central nervous system contributor to pain in FMS.